[New WHO recommendations for the treatment of leprosy].
D002991:Clofazimine / Q000008:administration & dosage / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007918:Leprosy / Q000145:classification / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008911:Minocycline / Q000008:administration & dosage / Q000627:therapeutic use; D009166:Mycobacterium leprae / Q000302:isolation & purification; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D012867:Skin / Q000473:pathology
D007917:Leprostatic Agents; D003622:Dapsone; D015242:Ofloxacin; D002991:Clofazimine; D008911:Minocycline; D012293:Rifampin
Nouvelles recommandations de l'OMS pour le traitement de la lèpre.